Bristol Myers Squibb Nabs Priority Review Tag for $3.15B Arthritis Drug Orencia to Prevent Transplant Rejection


Washington-based biotech company, Bristol Myers Squibb, has received a December 23rd decision date from the FDA.

If passed, Orencia, a drug originally approved for patients with rheumatoid arthritis, will be approved for use in patients older than six to prevent acute graft-versus-host disease.

The drug may even serve additional purposes as the National Institutes of Health completed a phase 3 study last year to determine if Orencia, when paired with another immune modulator drug, could potentially support immune reactions in severe covid cases.